FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2510985761> ?p ?o ?g. }

• W2510985761 endingPage "607" @default.
• W2510985761 startingPage "583" @default.
• W2510985761 abstract "The present study describes our continuous effort to develop epidermal growth factor receptor (EGFR) inhibitors based on the 6-aryl-pyrrolo[2,3-d]pyrimidin-4-amine scaffold. The activity-ADME space has been evaluated by synthesizing 43 new structures, including four variations of the 4-amino group and 34 different substitution patterns in the 6-aryl moiety. Most of the new pyrrolopyrimidines were highly active, with twelve analogues possessing lower IC50 values than the commercial drug Erlotinib in enzymatic assays. Ten EGFR inhibitors were also profiled in cell studies using the Ba/F3-EGFRL858R reporter cells, and all revealed nanomolar activity. However, some of the privileged structures in terms of potency had ADME short-comings: compounds containing amides, sulfonamides, amine and hydroxymethyl substituents in the 6-aryl group had low permeability and high efflux, derivatives having (R)-3-amino-3-phenylpropan-1-ol at C-4 induced hERG inhibition properties, and metabolic lability was seen for compounds having (S)-2-methoxy-1-phenylethan-1-amine at C-4. Based on a trade-off between enzymatic activity, cellular potency and ADME properties, (S)-2-phenyl-2-((6-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)ethan-1-ol appeared as the most promising drug candidate. Cellular studies indicate this compound to have therapeutic use in EGFR driven diseases." @default.
• W2510985761 created "2016-09-16" @default.
• W2510985761 creator A5007098021 @default.
• W2510985761 creator A5022171653 @default.
• W2510985761 creator A5044660021 @default.
• W2510985761 creator A5066430526 @default.
• W2510985761 creator A5069201284 @default.
• W2510985761 date "2016-11-01" @default.
• W2510985761 modified "2023-10-14" @default.
• W2510985761 title "Balancing potency, metabolic stability and permeability in pyrrolopyrimidine-based EGFR inhibitors" @default.
• W2510985761 cites W1237210351 @default.
• W2510985761 cites W1500036797 @default.
• W2510985761 cites W1517520371 @default.
• W2510985761 cites W1568436845 @default.
• W2510985761 cites W1965777226 @default.
• W2510985761 cites W1967676836 @default.
• W2510985761 cites W1975691556 @default.
• W2510985761 cites W1976996789 @default.
• W2510985761 cites W1979040485 @default.
• W2510985761 cites W1980316342 @default.
• W2510985761 cites W1982044762 @default.
• W2510985761 cites W1984784006 @default.
• W2510985761 cites W1985272763 @default.
• W2510985761 cites W1986989909 @default.
• W2510985761 cites W1991483463 @default.
• W2510985761 cites W1992000457 @default.
• W2510985761 cites W2013536577 @default.
• W2510985761 cites W2017323433 @default.
• W2510985761 cites W2027514622 @default.
• W2510985761 cites W2033409391 @default.
• W2510985761 cites W2038670745 @default.
• W2510985761 cites W2046822015 @default.
• W2510985761 cites W2050872970 @default.
• W2510985761 cites W2054732508 @default.
• W2510985761 cites W2058557855 @default.
• W2510985761 cites W2067282464 @default.
• W2510985761 cites W2067884089 @default.
• W2510985761 cites W2070269476 @default.
• W2510985761 cites W2083527129 @default.
• W2510985761 cites W2088642987 @default.
• W2510985761 cites W2090029719 @default.
• W2510985761 cites W2098412245 @default.
• W2510985761 cites W2100772783 @default.
• W2510985761 cites W2102630250 @default.
• W2510985761 cites W2103124714 @default.
• W2510985761 cites W2109091061 @default.
• W2510985761 cites W2114211001 @default.
• W2510985761 cites W2122010784 @default.
• W2510985761 cites W2139519829 @default.
• W2510985761 cites W2140452388 @default.
• W2510985761 cites W2141455139 @default.
• W2510985761 cites W2144001833 @default.
• W2510985761 cites W2150525034 @default.
• W2510985761 cites W2163607253 @default.
• W2510985761 cites W2326124692 @default.
• W2510985761 cites W2344420315 @default.
• W2510985761 cites W2414921169 @default.
• W2510985761 cites W2418690536 @default.
• W2510985761 cites W4210961589 @default.
• W2510985761 doi "https://doi.org/10.1016/j.ejmech.2016.08.068" @default.
• W2510985761 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27614407" @default.
• W2510985761 hasPublicationYear "2016" @default.
• W2510985761 type Work @default.
• W2510985761 sameAs 2510985761 @default.
• W2510985761 citedByCount "17" @default.
• W2510985761 countsByYear W25109857612017 @default.
• W2510985761 countsByYear W25109857612018 @default.
• W2510985761 countsByYear W25109857612019 @default.
• W2510985761 countsByYear W25109857612021 @default.
• W2510985761 countsByYear W25109857612022 @default.
• W2510985761 countsByYear W25109857612023 @default.
• W2510985761 crossrefType "journal-article" @default.
• W2510985761 hasAuthorship W2510985761A5007098021 @default.
• W2510985761 hasAuthorship W2510985761A5022171653 @default.
• W2510985761 hasAuthorship W2510985761A5044660021 @default.
• W2510985761 hasAuthorship W2510985761A5066430526 @default.
• W2510985761 hasAuthorship W2510985761A5069201284 @default.
• W2510985761 hasConcept C12554922 @default.
• W2510985761 hasConcept C131779359 @default.
• W2510985761 hasConcept C178790620 @default.
• W2510985761 hasConcept C185592680 @default.
• W2510985761 hasConcept C193042331 @default.
• W2510985761 hasConcept C200082930 @default.
• W2510985761 hasConcept C202751555 @default.
• W2510985761 hasConcept C2776568683 @default.
• W2510985761 hasConcept C2777752497 @default.
• W2510985761 hasConcept C2779362680 @default.
• W2510985761 hasConcept C2780263894 @default.
• W2510985761 hasConcept C2781076698 @default.
• W2510985761 hasConcept C3018358672 @default.
• W2510985761 hasConcept C55493867 @default.
• W2510985761 hasConcept C57992300 @default.
• W2510985761 hasConcept C69366308 @default.
• W2510985761 hasConcept C71240020 @default.
• W2510985761 hasConcept C83743174 @default.
• W2510985761 hasConcept C86803240 @default.
• W2510985761 hasConceptScore W2510985761C12554922 @default.
• W2510985761 hasConceptScore W2510985761C131779359 @default.

• next